Group 1 - The core stock of药捷安康 (02617) experienced a significant surge, with a cumulative increase of over 200% recently, followed by a sharp decline of 18% in early trading, currently down 12.99% at HKD 167.5, with a trading volume of HKD 333 million and a total market value dropping below HKD 70 billion [1] - The company has been included in the Hong Kong Stock Connect list effective from September 8, which may influence investor interest and trading activity [1] -药捷安康 focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, with a pipeline that includes six clinical-stage candidates and several preclinical candidates as of June 30, 2025 [1] Group 2 - The company reported a significant decline in other income and revenue, dropping from HKD 10.4 million in the first half of 2024 to HKD 3.6 million, a decrease of 65.1%, primarily due to reduced bank deposit interest and government subsidies [1] - Research and development costs decreased by 30.9% to HKD 98.4 million, indicating a potential focus on cost management [1] - The company recorded a pre-tax loss of HKD 123 million for the first half of the year, an improvement compared to a loss of HKD 160 million in the same period of 2024 [1]
港股异动 | 药捷安康(02617)早盘重挫18% 总市值不足700亿港元 上半年集团未取得主营业务收入